Pharmaceutical, biotech, and medical device companies face a challenging, competitive health landscape
Pharmaceutical, biotech, and medical device companies face a challenging, competitive health landscape. Pricing pressures, scientific breakthroughs, expanding demand for health care access, and emerging digital and analytic capabilities push companies to explore unconventional business models and build value-based customer relationships.
Underpinning all of this is the uncertainty created by Brexit negotiations. The implications of leaving the EU will be far-reaching for pharma and will impact across the life science ecosystem. Whilst companies need to be aware of the risks to their organisation, the UK’s Life Sciences Industrial Strategy offers opportunities for the UK to become more competitive as an environment and channel investment towards the pharma and life sciences industry.